Navigation Links
Johns Hopkins researchers identify new genetic risk factor for sudden cardiac death
Date:7/12/2011

In a large and comprehensive investigation into the underlying causes of sudden cardiac death (SCD) a surreptitious killer of hundreds of thousands annually in the United States researchers have discovered a variation in the genome's DNA sequence that is linked to a significant increase in a person's risk of SCD.

The new finding flags a DNA sequence called the BAZ2B locus, a region along the genome containing three genes previously unknown to play any role in cardiac biology, according to a report published online June 30 in PLoS Genetics. Understanding how genetic variation in this region plays a role in the risk of SCD could eventually help those at risk take steps to prevent it, the researchers say, although they emphasize that a great deal of follow-up work is required.

"Our analysis suggests that if you have one copy of this variant, your increased risk is double that of someone who doesn't," says Dan Arking, Ph.D., lead author of the study and an associate professor in the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. "If you have two copies having inherited one from each parent you have almost a fourfold increased risk of SCD."

Statistically significant though it is, this variant alone doesn't give scientists the information they need to proceed with a clinically useful test or therapy, Arking says. Scientists first need to figure out which of the three genes in the region is the key player, and determine how that gene's function is compromised likely by using model organisms to investigate their heart-related biological activity.

To identify the variant, a consortium of researchers first combined five separate genome wide association studies to survey each of the 3 billion base pairs in the DNA sequences of 1,283 individuals of European ancestry who experienced SCD, and more than 20,000 individuals without SCD. They followed up suggestive findings in an additional 3,119 SCD cases and 11,146 non-SCD control subjects from 11 European ancestry studies to confirm that the BAZ2B locus is associated with SCD.

Collecting enough DNA samples to yield statistical power has been a challenge for investigators studying SCD, Arking says. One reason is that most individuals who experience it do not have clinical signs that would suggest that they are at high-risk for SCD. In addition, only about 10 percent of people survive their initial sudden death events. (Even if the heart stops beating, a person might be saved if the heart is shocked quickly enough back into normal rhythm. The episode is still considered a sudden death event, even if the person survives, because death would have occurred without intervention.)

"SCD is a distinct disorder that involves an electrical instability in the heart," Arking says. "It's what happens when a 40-year-old guy one minute is feeling great, working out on a treadmill, and the next minute, without warning, drops dead."

Arking emphasized that based on their analyses, plenty of people are walking around with the BAZ2B variant who don't experience sudden death. SCD is a complex disease, he says, meaning this newly identified risk factor is neither necessary nor sufficient as its cause. The variant is independent of other risk factors for sudden cardiac death, which include diabetes, heart attack, and a prolonged QT interval, a measure of electrical activity in the heart obtained from a standard electrocardiogram (ECG).

"While we've done a great job of treating coronary disease and reducing the risk of heart attacks, we've made very little progress in reducing the risk of sudden cardiac death," Arking says. "The use of genetics to screen broadly is critical because we don't have other measures that will do a good job of identifying people at risk."


'/>"/>

Contact: Maryalice Yakutchik
myakutc1@jhmi.edu
443-287-2251
Johns Hopkins Medical Institutions
Source:Eurekalert

Related biology news :

1. Johns Hopkins researchers awarded $32 million
2. Johns Hopkins scientists expose cancer cells universal dark matter
3. Johns Hopkins researchers link cell division and oxygen levels
4. Johns Hopkins scientists reveal nerve cells navigation system
5. Texas researcher Arthur E. Johnson to give prestigious ASBMB-Lipmann Lectureship
6. Johns Hopkins team creates stem cells from schizophrenia patients
7. Johns Hopkins researchers capture jumping genes
8. Encyclopedia of Life names Dr. Rebecca Johnson a 2011 Rubenstein Fellow
9. Johns Hopkins researchers reshape basic understanding of cell division
10. UNCs Dr. Sean McLean receives Robert Wood Johnson Foundation award
11. American Society for Microbiology honors Ryan Johnson
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology: